RxDoctor Payments Data

Joseph Guarnaccia, MD

Neurology · Derby, CTNPI 1235164427

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $244,108 of the $304,415 with a category attached, or 80.2%. 11 manufacturers reported payments, led by Biogen at 32.7% of the total. Reporting peaked in 2019 at $114,681 and has fallen 100.0% since, to $54 in 2025. Among neurology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$304,415in general payments, 2019–2025

Across 370 payments — averaging $822.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$100K
  • EMD Serono, Inc.$80K
  • Genentech USA, Inc.$42K
  • E.r. Squibb & Sons, L.L.C.$31K
  • Novartis$22K
  • Sanofi$16K
  • plus $14K from 5 others

What the payments were for

  • Consulting fees$40,04013%
  • Speaking & faculty fees$244,10880%
  • Travel & lodging$12,6554%
  • Food & beverage$7,3782%
  • Education$2350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$304,415 in reported general payments places this provider in the 95th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$44,764
Medicare patients
181
Services billed
403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab194$1,860,197
CopaxoneGlatiramer Acetate100$629,470
TecfideraDimethyl Fumarate64$492,205
Avonex Pen (4 Pack)Interferon Beta-1a29$381,449
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5036$276,525
OctagamImmun Globg(Igg)/Malt/Iga Ov5014$175,247
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5027$137,930
AmpyraDalfampridine32$130,801
AubagioTeriflunomide13$107,420
Avonex (4 Pack)Interferon Beta-1a11$101,454
Dalfampridine ErDalfampridine260$78,444
Glatiramer Acetate38$72,574
NuedextaDextromethorphan Hbr/Quinidine38$60,991
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5014$48,799
Dimethyl Fumarate74$45,246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Avonex (4 Pack)$99,543$593,65975 claims
SanofiAubagio$15,668$107,42013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 280 neurology providers in Connecticut.

Other neurology in Derby

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →